Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Karyopharm Expanded Access Program for Selinexor

NCT07215832 is registered in ClinicalTrials.gov with Karyopharm Therapeutics Inc as lead sponsor.

NCT NCT07215832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07215832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Karyopharm Expanded Access Program for Selinexor
Lead sponsor
Karyopharm Therapeutics Inc
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma (dlbcl), endometrial cancer, multiple myeloma, myelofibrosis, neuroglioblastoma, other, peripheral t-cell lymphoma, sarcoma